1
|
Cruz-Bautista I, Mehta R, Cabiedes J, García-Ulloa C, Guillen-Pineda LE, Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Determinants of VLDL composition and apo B-containing particles in familial combined hyperlipidemia. Clin Chim Acta 2014; 438:160-5. [PMID: 25172037 DOI: 10.1016/j.cca.2014.08.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2014] [Revised: 07/31/2014] [Accepted: 08/18/2014] [Indexed: 10/24/2022]
Abstract
BACKGROUND In familial combined hyperlipidemia (FCHL) the severity of the dyslipidemia is determined by an overproduction of VLDL (very low density lipoprotein) particles and by its abnormal lipid composition. However, few are known regarding the metabolic factors that determine these abnormalities. We investigated the impact of metabolic factors on the number of atherogenic particles (apolipoprotein B level (apoB)) and the triglyceride content of very low-density lipoproteins (VLDLs-TG). METHODS A cross-sectional study done in FCHL subjects and gender and age-matched healthy subjects. A clinical assessment, lipid profile and plasma concentrations of insulin, apolipoprotein CIII (apo CIII), apolipoprotein AII (apo AII), high sensitive C-reactive protein (HS-CRP), adiponectin and leptin were documented in 147 FCHL patients and 147 age-matched healthy subjects. Multivariate regression models were performed to investigate the independent determinants of VLDL-TG and apo B levels adjusting for confounding factors. RESULTS The variables that determined the VLDL-triglyceride content as a surrogate of VLDL composition were apo CIII (β=0.365, p<0.001), insulin (β=0.281, p<0.001), Apo AII (β=0.145, p<0.035), and adiponectin levels (β=-0.255, p<0.001). This model explained 34% of VLDL composition (VLDL-TG) variability. However, none of these variables were independent contributors of apo B-containing particles. CONCLUSIONS In patients with FCHL apo CIII, apo AII and adiponectin are major novel factors determining the VLDL particle composition. However, such factors do not explain apo B-containing particles.
Collapse
Affiliation(s)
- Ivette Cruz-Bautista
- Endocrinology and Metabolism Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, 14000 Mexico City, Mexico
| | - Roopa Mehta
- Endocrinology and Metabolism Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, 14000 Mexico City, Mexico
| | - Javier Cabiedes
- Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, 14000 Mexico City, Mexico
| | - Cristina García-Ulloa
- Endocrinology and Metabolism Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, 14000 Mexico City, Mexico
| | - Luz Elizabeth Guillen-Pineda
- Endocrinology and Metabolism Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, 14000 Mexico City, Mexico
| | - Paloma Almeda-Valdés
- Endocrinology and Metabolism Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, 14000 Mexico City, Mexico
| | - Daniel Cuevas-Ramos
- Endocrinology and Metabolism Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, 14000 Mexico City, Mexico
| | - Carlos A Aguilar-Salinas
- Endocrinology and Metabolism Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, 14000 Mexico City, Mexico.
| |
Collapse
|
2
|
Koike T, Kitajima S, Yu Y, Li Y, Nishijima K, Liu E, Sun H, Waqar AB, Shibata N, Inoue T, Wang Y, Zhang B, Kobayashi J, Morimoto M, Saku K, Watanabe T, Fan J. Expression of Human ApoAII in Transgenic Rabbits Leads to Dyslipidemia. Arterioscler Thromb Vasc Biol 2009; 29:2047-53. [DOI: 10.1161/atvbaha.109.190264] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Apolipoprotein AII (apoAII) is the second major apolipoprotein in high-density lipoprotein (HDL). However, the physiological functions of apoAII in lipoprotein metabolism have not been fully elucidated.
Methods and Results—
We generated human apoAII transgenic (Tg) rabbits, a species that normally does not have an endogenous apoAII gene. Plasma levels of human apoAII in Tg rabbits were ≈30 mg/dL, similar to the plasma levels in healthy humans. The expression of human apoAII in Tg rabbits resulted in increased levels of plasma triglycerides, total cholesterol, and phospholipids accompanied by a marked reduction in HDL-cholesterol levels compared with non-Tg littermates. Analysis of lipoprotein fractions showed that hyperlipidemia exhibited by Tg rabbits was caused by elevated levels of very-low-density lipoproteins (VLDL) and intermediate-density lipoproteins. Furthermore, postheparin lipoprotein lipase activity significantly decreased in Tg rabbits compared with non-Tg rabbits.
Conclusions—
These results indicate that apoAII plays an important role in both VLDL and HDL metabolism, possibly through the inhibition of lipoprotein lipase activity. ApoAII Tg rabbits may become a new model for the study of human familial combined hyperlipidemia.
Collapse
Affiliation(s)
- Tomonari Koike
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Shuji Kitajima
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Ying Yu
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Ying Li
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Kazutoshi Nishijima
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Enqi Liu
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Huijun Sun
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Ahmed Bilal Waqar
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Nobumitsu Shibata
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Tomoriho Inoue
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Yao Wang
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Bo Zhang
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Junji Kobayashi
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Masatoshi Morimoto
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Keijiro Saku
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Teruo Watanabe
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| | - Jianglin Fan
- From the Department of Molecular Pathology (T.K., Y.Y., Y.L., A.B.W., N.S., T.I., Y.W., J.F.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Japan; the Analytical Research Center for Experimental Sciences (S.K., K.N.), Saga University, Japan; the Laboratory Animal Center (E.L.), Xi'an Jiaotong University School of Medicine, China; the Department of Pharmacology (H.S.), Dalian Medical University, China; the Department of Cardiology (B.Z., K.S.), Fukuoka
| |
Collapse
|